Parkinsonism and tremor disorders.
A clinical approach

Hani TS Benamer
New Cross Hospital, Wolverhampton and Queen Elizabeth Neuroscience Centre, University Hospital Birmingham, UK

Abstract: Differentiation of idiopathic Parkinson's disease from other causes of Parkinsonism, such as Multiple System Atrophy, Progressive Supranuclear Palsy and Vascular Parkinsonism can be difficult. Clinico-pathological studies suggest that the clinical diagnosis of idiopathic Parkinson's disease is 76% reliable. Also, clinical differentiation of tremor prominent Parkinsonism from Essential Tremor or Drug induced Parkinsonism may be problematic, especially in the early stages of the disease. Since these disorders are obviously different in clinical progress, it is important for the clinician to address the patient's and family's concerns about prognosis from a firm diagnostic footing. In this article the clinical features of the common and important causes of Parkinsonism and tremor disorders are reviewed and a practical approach is suggested.

Key Words: Idiopathic Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Vascular Parkinsonism, Essential Tremor, Drug induced Parkinsonism.

Introduction
James Parkinson first described Parkinson's disease in 1817 in his famous Essay on the "Shaking Palsy" [1]. Since then there have been huge developments and changes in the understanding of the pathophysiology, clinical features and treatment of the disease, which carries his name. However, the diagnosis is still a clinical one and there are no biological markers to diagnose this condition. In the majority of patients the diagnosis of idiopathic Parkinson’s disease seems straightforward. However, many patients with Parkinsonism and tremor disorders exhibit a diagnostic challenge particularly in the early stage of the illness. Clinico-pathological studies have shown that 24% of patients with a clinical diagnosis of idiopathic Parkinson’s disease (made by a neurologist or geriatrician) do not fulfill pathological criteria and have an alternative diagnosis [2,3]. Multiple system atrophy, progressive supranuclear palsy and vascular disease are the main pathological diagnoses in such cases. The bias introduced by these pathological studies when compared to a clinical setting is in the absence of essential tremor and drug induced Parkinsonism.

Why is it important to differentiation between idiopathic Parkinson’s disease and other causes of Parkinsonism and tremor disorders especially in the early stages? Firstly, there are differences in clinical progress and survival from the more benign essential tremor through idiopathic Parkinson’s disease to multiple system atrophy or progressive supranuclear palsy. Therefore, it is appropriate for the clinician to address the patient’s and family’s concern about prognosis and provide accurate prognostic information. Secondly, introduction and amendment of drug therapy is tailored to the patients' condition and progress, e.g. patients suspected to have idiopathic Parkinson’s disease in whom a revised diagnosis of essential tremor is reached, can have levodopa withdrawal. Finally, an accurate diagnosis would help in understanding the aetiology and pathophysiology of different causes of Parkinsonism and tremor disorders, and define accurately a patient cohort for clinical research studies.

In this article the clinical features of idiopathic Parkinson’s disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) and Vascular Parkinsonism (VP) as well as Essential Tremor (ET) and Drug Induced Parkinsonism (DIP) will be discussed.

Definition and classification of parkinsonism: Parkinsonism is a clinical syndrome characterised by bradykinesia: slowness of movement, hypokinesia: reduced movement, akinesia: loss of movement, rigidity: increased resistance to passive extension and flexion, tremor: mainly resting.

Parkinsonism may be classified as:
1. Idiopathic Parkinson’s disease, of unknown aetiology.
2. Parkinsonism as part of other neurodegenerative disorders, such as MSA, PSP.
3. Parkinsonism with identifiable causes, such as VP and DIP.

Idiopathic Parkinson’s Disease (PD): Idiopathic Parkinson's disease consists of Parkinsonism characterised pathologically by neuronal loss with Lewy bodies in the substantia nigra. Lewy bodies, which are eosinophilic intracytoplasmic inclusions first described by F H Lewy in 1914, are not specific for PD. Other conditions such as MSA, PSP, and Lewy body dementia were shown to have Lewy bodies. Also, Lewy bodies can be found as an incidental finding in elderly patients without clinical features of PD, which probably represent pre-clinical or early stages of PD [4-7].

Idiopathic Parkinson’s disease is the common cause of parkinsonism, with an annual incidence of 20.5 per 100 000 of the population and prevalence 164 per 100 000 [8-10]. The prevalence of the disease increases with age from 47 per 100 000 for ages 40-49 years, to 832 per 100 000 for 70-79 years [10]. The mean age at onset PD is between 55-65 years, with a slight
male predominance of 60%, and mean age of death is 75.5 years [10-12]. The majority of patients with Parkinson’s disease have no family history of Parkinsonism. However, some patients with positive family history could have the familial form of Parkinsonism especially patients with young onset disease. Several genetic variants have been identified such as the parkin gene in both autosomal recessive and dominant forms. Some of these cases do not have Lewy bodies. Over the next few years the understanding of the genetics of Parkinsonism would modify our views about the aetiology of PD [13,14].

Patients usually present with non-specific pains and aches, stiffness, changes in the handwriting, or general slowing down. Examination usually shows loss of arm swing, tendency to drag a leg, difficulty with hand movements, loss of facial expression, reduced voice volume, lead-pipe rigidity or cog-wheel rigidity if tremor is superimposed and tremor mainly at rest. The onset is asymmetric in 72% of the patients. Tremor is the presenting features in 70% of patients but 42% have tremor only without bradykinesia or rigidity and 11% have tremor dominant disease hence the name Benign Tremulous Parkinson's disease, which has a better prognosis than the akinetic rigid presentation. In the late stages of PD patients develop speech and swallowing difficulties. Also, falls, gait problems, autonomic dysfunction and dementia (up to 40%) are late features. Almost every patient with PD responds to levodopa therapy [11].

Table 1: Summary of clinical features of idiopathic PD
- Three Subtypes: Tremor dominant (26%),
- Akinetic-rigid (38%) and - Mixed type (36%).
- Bradykinesia and tremor and/or rigidity.
- Unilateral onset with persistent asymmetry affecting the side of the onset most (Hemi-parkinsonism).
- Arms are more involved than legs.
- Excellent response to levodopa.

Multiple System Atrophy (MSA)
MSA is a sporadic, adult onset, neurodegenerative disease. It is a clinico-pathological entity, which can present with any combination of Parkinsonism, cerebellar and/or pyramidal signs and autonomic dysfunction. Pathologically, it is characterised by cell loss and gliosis and α-synuclein positive oligodendroglial cytoplasmic inclusions in a selection of brain structures such as: substantia nigra, striatum, locus coerules, pontine nuclei, cerebellar purkinje cells, inferior olives, and Onuf’s nucleus in the spinal cord [15-18]. Shy and Drager described in 1960 a neurological syndrome associated with orthostatic hypotension [19]. In 1969, Graham and Oppenheimer introduced the term MSA. [20] but it has since become a title, which covers a wide range of different degenerative conditions [15].

The following subtypes of MSA have been defined in a clinico-pathological study: [21].
(i) Shy-Drager syndrome, in which autonomic failure predominates.
(ii) Striatonigral degeneration, in which Parkinsonism predominates.
(iii) Olivopontocerebellar atrophy, in which cerebellar features predominate.

However, Oertel and Quinn [22] argue against using the term Shy-Drager syndrome because autonomic dysfunction is almost universal in MSA. [21] They define MSA subtypes as follows:
(i) Striatonigral degeneration (MSA-parkinsonian type or MSA-P).
(ii) Sporadic olivopontocerebellar atrophy (MSA-cerebellar type or MSA-C).

There are no definite incidence figures for this disorder and it has been postulated that MSA contributes between 3.6 and 22% of incident cases of parkinsonism [15, 16,19-24]. MSA-P is 2 to 4 times more common than MSA-C. MSA is slightly more common in male patients, with a mean age of onset of 54 years, mean age at death of 60 years and mean duration of illness of 6-9 years [23,24].

Autonomic dysfunction is usually present in almost all patients and impotence is the most common feature in males. Postural faintness, urinary incontinence and/or urinary retention are other features. Half of the cases have cerebellar signs, mainly gait ataxia, and pyramidal signs can be demonstrated in 50% of MSA patients. Parkinsonism occurs in the majority of cases, with akinesia as the more common feature, rest tremor in less than half of cases and classical pill-rolling tremor seen only in 10% of patients. Other features included stridor and muscular contractions while dementia is rarely a feature of MSA. Only a third of patients show some response to levodopa, which is usually unsustainable [23,24].

Table 2: Summary of clinical features of MSA
- Two Subtypes: MSA-P and MSA-C.
- Mainly symmetrical bradykinesia and rigidity.
- Features of autonomic dysfunction.
- Cerebellar signs and pyramidal signs.
- Stridor, and muscular contractions.
- Dementia is rare.
- Poor response to levodopa.
**Progressive Supranuclear Palsy (PSP) or Steele-Richardson-Olszewski Syndrome**

In 1964 Steele, Richardson and Olszewski described the clinical and pathological features of nine patients with a progressive disorder of vertical gaze, axial rigidity, dysarthria, pseudobulbar palsy and mild dementia, which they called progressive supranuclear palsy [25]. Pathologically PSP is characterised by the presence of neurofibrillary tangles and neurtirol threads and tufted astrocytes within the following areas: pallidum, subthalamic nucleus, substantia nigra, midbrain and pontine reticular formation. These distinctive histopathological inclusions are made up of insoluble aggregation of tau phosphoprotein. Tau-positive glial inclusions are a pathological feature of PSP [26].

PSP is under-diagnosed, making accurate epidemiological data difficult to obtain. Several studies showed a prevalence between 1.39 to 6.5 per 100 000 [27,28]. Annual incidence of 3.1 to 4.0 cases per million has been estimated in one study [27].

PSP is a sporadic disorder, but familial cases have been described [29, 30]. It is slightly more common in males and usually presents in the seventh decade. Postural instability and falling are the presenting features in more than 50% of patients, and dysarthria in one third. Visual disturbances in the form of diplopia, blurred vision, burning eyes, and light sensitivity are the initial symptoms in around 15% of patients. Cognitive or behavioural changes generally follow [31-33]. Other clinical features include; bilateral bradykinesia, axial rigidity, speech changes (dysphonic, palilalia, ataxic and unintelligible speech), frontal lobe symptoms, personality changes, dysphagia and neck dystonia [34]. Vertical downward palsy is the single most important clinical feature of PSP. Although upward gaze and convergence become impaired, this also occurs in other basal ganglia disorders and in old age [31]. The oculocephalic manoeuvre remains intact (except in very advanced stages), and it is this characteristic that makes the disorder supranuclear [35, 36]. Other ocular manifestations include supranuclear opthalmoplegia, absent Bell's phenomenon, impaired pupillary light reflexes, lid retraction, a markedly reduced blink rate, frontalis muscle overactivity, blepharospasm, and apraxia of eye opening or closure [31, 37]. These changes give the patient a fixed, staring, and astonished expression [31]. Although the presence of down-gaze palsy is an essential finding to secure the diagnosis of PSP, there are a few pathologically proven cases reported who had not developed such abnormality during life [34,37].

| Table 3: Summary of clinical features of PSP |
|---------------------------------------------|
| - Postural instability and falls.          |
| - Symmetrical bradykinesia and rigidity.   |
| - Cognitive or behavioural.                |
| - Dysarthria and speech changes.           |
| - Vertical downward palsy with intact oculocephalic manoeuvre. |
| - Poor response to levodopa                |

**Vascular Parkinsonism (VP)**

The concept of VP was introduced when Critchley in 1929 described 5 types of clinical presentations of what was termed arteriosclerotic Parkinsonism [38]. Rigidity, fixed faces and short-stepping gait were the main clinical signs. Pseudo-bulbar, dementia, incontinence, pyramidal or cerebellar signs were considered as additional features. After several clinical studies in the 1960’s and 1970’s showed no relation between arteriosclerosis and PD, Critchley in 1981 renamed the condition arteriosclerotic pseudo- parkinsonism [39-42]. With the development of CT and MRI the concept of VP was revived, but there are no generally accepted clinical criteria to diagnose this condition [43-45].

Several clinical features have been described relating brain vascular lesions to Parkinsonism. An insidious onset of parkinsonism, at times indistinguishable from PD, including a response to levodopa, due to brain vascular infarcts has been described [3,12,44-47]. On the other hand, two patients presented with acute onset Parkinsonism, due to vascular lesions in the basal ganglia, and recovery without anti-parkinsonian drugs had been reported [48,49].

Lower body Parkinsonism (LBP) is another term used to describe patients with VP and it represents a group of patients, probably hypertensive, who usually have gait difficulty, symmetrical rigidity, absent tremor, and no or some response to levodopa therapy [50-52].

The association of ischaemic stroke and vascular risk factors was addressed in two studies, where the incidence of ischaemic stroke among PD patients was lower than controls in one study but an association was found in another [53-54]. Thus PD may co-exist with cerebrovascular disease, but there may be a lower probability of a chance association because of the risk factor profiles for each disease. Post-mortem studies provide definite evidence that PD patients may also have cerebrovascular disease, and that patients with parkinsonism may have cerebrovascular disease but no pathological features of PD [3]. The clearest clinical description of Parkinsonism in association with cerebrovascular disease is that of LBP. However, upper body signs and symptoms are not excluded in such patients, and a vascular aetiology for patients with less than pure lower body features appears possible.

Finally, a small subset of patients may be unfortunate enough to have predominately upper body features from PD and lower body features from VP.
Essential Tremor (ET)

Essential tremor is the most common movement disorder, with a worldwide prevalence estimated at between 4 and 39 per 1000. The annual incidence is about 23 per 100,000 population [55, 56]. A bimodal distribution with peaks in the second and fifth decades has been reported with men and women equally affected, [57,58] but other studies indicate an onset usually around 45 years with an earlier onset in familial cases [59]. Penetrance is usually complete by the age of 65 years, and no evidence of the disease skipping a generation was found in studying 20 kindreds, thereby indicating autosomal dominant inheritance [58]. However, no responsible gene has yet been identified [60].

Typically the tremor is postural and therefore occurring while voluntarily maintaining position against gravity and mainly involving hands and forearm, starting intermittently and progressing to become permanent, rarely remitting and usually worsened by emotion [61]. Tremor of the head, voice, tongue, and legs may follow [57,58]. ET is different from parkinsonian tremor, which is mainly resting and therefore occurs in muscles, which are completely supported against gravity [62, 63]. Although this description implies a clear separation of the tremor types, there is often a degree of overlap making ET one of the conditions which is about 23 per 100,000 population [55, 56]. A bimodal distribution with peaks in the second and fifth decades has been reported with men and women equally affected, [57,58] but other studies indicate an onset usually around 45 years with an earlier onset in familial cases [59]. Penetrance is usually complete by the age of 65 years, and no evidence of the disease skipping a generation was found in studying 20 kindreds, thereby indicating autosomal dominant inheritance [58]. However, no responsible gene has yet been identified [60].

Table 4: Summary of clinical features of VP

| - Gait difficulty, symmetrical rigidity, absent tremor (lower body Parkinsonism). |
| - An insidious onset of parkinsonism indistinguishable from PD. |
| - Acute onset parkinsonism, due to vascular lesions in the basal ganglia. |
| - Modest or poor response to levodopa. Occasionally good response. |

Table 5: Summary of clinical features of ET

- Mainly postural tremor but an overlap with resting tremor can be seen.
- No rigidity or bradykinesia.
- Positive family history.
- Improvement with alcohol.
- Treatment mainly with beta blockers particularly propranolol.

Drug Induced Parkinsonism (DIP)

DIP is the most frequent neuroleptic induced side effect. Both Phenothiazines and non-phenothiazines can induce parkinsonism in 10-15% of psychotic patients treated with these drugs [81,82]. Anti-emetic drugs such as prochlorperazine and metoclopramide can cause Parkinsonism [83-85]. Other drugs such as sodium valproate, tetrabenazine and calcium-channel blockers such as cinnarizine are also reported to cause DIP [86-88]. DIP unmasked PD can be difficult to distinguished from pure DIP, especially that DIP could take some months if not years to reverse on withdrawal of the offending drug [89]. Stopping the offending drug is obviously the treatment of choice in DIP however; this could be difficult especially with neuroleptic drugs. Anticholinergic, amantadine and pyridoxine may help in reducing the parkinsonian symptoms in patients with DIP [90,91].

Table 6: Summary of clinical features of DIT

- Neuroleptic drugs are the most frequent cause of DIP.
- If possible the offending drug should be stopped.
- Parkinsonism can take a long time to resolve after stopping the offending drugs.
- Anticholinergic amantadine and pyridoxine could help.

Summary

Parkinsonism and tremor disorders could represent a diagnostic challenge. However, a good clinical assessment usually helps in reaching a final diagnosis but sometimes the patient needs...
to be assessed several times before a clear diagnosis emerges due to lack of diagnostic investigation.

The clinicians should be alert to the unusual symptoms and signs such as: a) Absent or poor response to levodopa, b) Rapid disease progression, c) Autonomic failure, d) Early falls, e) Cerebellar and/or pyramidal signs, f) Supranuclear palsy, g) Lower body Parkinsonism, h) Early dementia.

I suggest the following practical approaches to patients presenting with parkinsonism and/or tremor:

1) Confirm that the patient has parkinsonian features, 2) Always think of essential tremor when tremor is the prominent feature and there is no gait problem nor difficulty to rise from a low chair, 3) Ask about drug history, 4) Ask about symptoms of autonomic dysfunction, 5) Ask about early falls, 6) Check for pyramidal and cerebellar signs, 7) Measure the blood pressure, supine and erect, 8) Check eye movements, 9) Check the Mini-mental test, 10) If not sure whether the patient has PD or other diseases (MSA, PSP, VP) try L-dopa.

With being alert to the unusual features and following a systemic approach the likelihood of getting the diagnosis right is high although this may take some time.

References

1. Parkinson J. An Essay on the Shaking palsy. London Sherwood, Neely, and Jones, 1817.
2. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism- A prospective study. Can J Neuro Sci 1991; 18:275-8.
3. Hughes AJ, Daniel SE, Kliford L, Rees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol, Neurosurg and Psychiatry 1992; 55:181-4.
4. Gibb WRG. The Lewy body in autonomic failure. In Bannister R: Autonomic failure; Oxford University Press 1988; 484-7.
5. Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neurol Transm 1980; 16(suppl):111-8.
6. Gibb WRG. Neuropathology in movement disorders. J Neurol, Neurosurg and Psychiatry 1989; (special suppl):55-67.
7. Forno LS. Concentric hyaline intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases). Relationship to Parkinsonism. J Am Geriatr Soc 1969; 17:557-75.
8. Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ 1995; 310:447-52.
9. Rajput AH, Olford KP, Beard MC, Kurland LT. Epidemiology of Parkinsonism: Incidence, classification, and mortality. Ann Neurol 1984; 16:278-82.
10. Mutch WJ, Dingwell-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's Disease in a Scottish city. BMJ 1986; 292:534-6.
11. Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-42.
12. Hughes AJ, Daniel SE, Blankson S, Rees AJ. A clinico-pathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-8.
13. Gwinn-Hardy K. Genetics in Parkinsonism. Mov Disord 2002; 17:693-700.
14. Lewthwaite AJ, Nicholl D. Genetics in Parkinsonism. Curr Neurol Neurosci Rep 2005; 5:397-404.
15. Quinn N. Multiple system atrophy. In Marsden CD and Fahn S Movement disorders 3 Butterworths 1994; 262-81.
16. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol, Neurosurg and Psychiatry 1995; 58:160-6.
17. Papp M, Khan JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94:79-100.
18. Wakabayashi K, Yoshimoto M, Tsuji S, Takahasi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249:180-2.
19. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol 1960; 2:556-61.
20. Graham JG, Oppenheimer DR. Orthostatic hypotension and nictine sensitivity in a case of multiple system atrophy. J Neurol, Neurosurg and Psychiatry 1969; 32:28-34.
21. Litvan I, Goetz G, Jankovic J, Wenning G et al. What is the accuracy of clinical diagnosis of multiple system atrophy? A clinico-pathologic study. Arch Neurol 1997; 54:937-44.
22. Oertel W, Quinn N. Movement disorders. In Brandt T, Caplan LR, Dichtfans J, Diener HC, and Kennard C. Neurological disorders course and treatment. Acedemic Press 1996; 64:715-72.
23. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. Brain 1994; 117:835-45.
24. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple System Atrophy: A review of 203 pathologically proven cases. Movement Disorders 1997; 12:133-47.
25. Steele JC, Richardson JC, Olszewski J. Progressive Supranuclear Palsy. Arch Neurol 1964; 10:333-59.
26. Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewske Syndrome (Progressive Supranuclear Palsy). Neurology 1994; 44:2015-9.
27. Golbe LI, Davis PH, Schoenbery BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38:1031-4.
28. Nath U, Ben-Shlomo Y, Thomson R, Morris HR, Wood NW, Lees AJ, Burn DJ. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124:1438-49.
29. de Yebenes JG, Sarasa JL, Daniel SE, Lees AJ. Familial progressive supranuclear palsy: Description of a pedigree and review of the literature. Brain 1995; 118:1095-103.

30. Brown J, Lantos P, Stratton M, Rogues P, Rossor M. Familial progressive supranuclear palsy. J Neurol, Neurosurg and Psychiatry 1993; 56:473-6.

31. Lees AJ, Steele-Richardson- Olszewski Sydrome (progressive supranuclear palsy). In Marsden and Fahn. Movement disorders 2. Butterworths 1987: 272-84.

32. Litvan I, Mangone CA, Mckee A, Verry M, Parsa A, Jellinger K, D’Olhaberriague L, Chaudhuri KR, Pearce RKB. Natural history of progressive supranuclear palsy (Steele-Richardson- Olszewski Sydrome) and clinical predictors of survival: a clinicopathological study. J Neurol, Neurosurg and Psychiatry 1996; 61:615-20.

33. Nath U, Ben-Shiomy Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60:910-6.

34. Duvoisin RC, Golbe LI, Lepore FE. Progressive Supranuclear Palsy. Can J Neuro Sci 1987; 14:547-54.

35. Jankovic J. Progressive Supranuclear Palsy. Neurol Clinics 1984; 2:473-86.

36. Stell R, Bronstein AM. Eye movement abnormalities in extrapyramidal disease. In Marsden and Fahn. Movement disorders 3. Butterworths 1994: 88-113.

37. Collins SJ, Ahisky JE, Parisi JE, Maraganore DM. Progressive Supranuclear Palsy: neuropathologically based diagnostic clinical criteria. J Neurol, Neurosurg and Psychiatry 1995; 58:167-73.

38. Critchley M. Arteriosclerotic Parkinsonism. Brain 1929; 52: 23-83.

39. Eadie MJ, Suterland JM. Arteriosclerosis in Parkinsonism. J Neurol Neurosurg Psychiatry 1964; 27:237-40.

40. Parkes JD, Marsden CD, Rees JE, Curzon G, Kantamaneni BD, Knil-Jones R, Akbar A, Das S, Kataria M. Parkinson’s disease, cerebral arteriosclerosis, and senile dementia. Quarterly J Med 1974; 169:49-61.

41. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some other previous infections in etiology of Parkinson’s disease: A case control study. Clin Neurol Neurosurg 1976; 79:46-56.

42. Critchley M. Arteriosclerotic pseudo-parkinsonism. In Rose C, Capildeo R (Eds) Research progress in Parkinson’s disease. London: Pitman Medical 1981; 40-2.

43. Chang CM, Yu YL, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol Scand 1992; 86:586-92.

44. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. Basal ganglia lacunes and parkinsonism. Neuroepidemiology 1994; 13:108-12.

45. der-GrosWasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lacunar infarcts of the basal ganglia. Eur Neurol 1995; 35:46-49.

46. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia inaracts. Neurology 1984; 34:1516-8.

47. Murrow RW, Schweiger GD, Kepes JI, Koller WC. Parkinsonism due to a basal ganglia lacunar state: Clinicopathologic correlation. Neurology 1990; 40:897-900.

48. Friedman A, Kang UJ, Tatemichi TK, Burke R. A case of parkinsonism following striatal lacunar infarction (Letter). J Neurol Neurosurg Psychiatry 1986; 49:1087-8.

49. Mayo J, Arias M, Leno C, Berciano J. Vascular parkinsonism and periarteritis nodosa (Letter). Neurology 1986; 36:874.

50. FitzGerald PM, Jankovic J. Lower Body Parkinsonism: Evidence for vascular etiology. Mov Disord 1989; 4:249-60.

51. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke1997; 28:965-9.

52. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999; 56:98-102.

53. Struck LK, Rodytitsky L, Dobson JK. Stroke and its modification in Parkinson’s disease. Stroke 1990; 21:1395-9.

54. Levine RL, Jones JC, Bee N. Stroke and Parkinson’s disease. Stroke 1992; 23:839-42.

55. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorders? Estimates of the prevalence of essential tremor throughout the world. Movement Disorders 1998; 13:5-10.

56. Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol, Neurosurg and Psychiatry 1984; 47:66-70.

57. Lou J, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology 1991; 42:234-8.

58. Bain PG, Findley LJ, Thompson PD, Gresty MA, Rothwell JC, Harding AE, Marsden CD. A study of hereditary essential tremor. Brain 1994; 117:805-24.

59. Koller WC, Busenbark K, Miner K, et al. The relationship of essential tremor to other movement disorders: Report on 678 patients. Ann Neurol 1994; 35:717-23.

60. Britton TC. Essential tremor and its variants. Current Opinion in Neurology 1995; 8:314-9.

61. Larsen TA, Calne DB. Essential tremor. Clin Neuropharmacol 1983; 6:185-206.

62. Findley LJ, Koller WC. Definitions and behavioural classifications. In Findley and Koller. Handbook of tremor disorders. New York: Marcel Dekker, 1995: 1-5.

63. Findley. Classification of tremors. J Clinical Neurophysiology 1996; 13:122-32.

64. Martinelli P, Gabellini AS, Gulli MR, Lugaresi E. Different clinical features of essential tremor: a 200-patients study. Acta Neurol Scand 1975; 75:106-11.

65. Marttila RJ, Rautakorpi IL, Rinne UK. The relation of essential tremor to Parkinson’s disease. J Neurol, Neurosurg and Psychiatry 1984; 47:734-5.

66. Clevees L, Findley L, Koller W. Lack of association between essential tremor and Parkinson’s disease. Ann Neurol 1998; 24:23-26.

67. Geraghty JJ, Jankovic J, Zetkusy WJ. Association between essential tremor and Parkinson’s disease. Ann Neurol 1985; 17:329-3.
Parkinson's disease, essential tremor, and control subjects. Neurology 1995; 45:645-8.

69. Rajput AH, Rozdilsky B, Ang L, Rajput A. Clinicopathologic observations in essential tremor. Neurology 1991; 41:1422-4.

70. Rajput A, Robinson CA, Rajput AH. Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology 2004; 63:1541-2.

71. Salemi G, Savetti G, Rocca WA et al. Prevalence of essential tremor: A door-to-door survey in Terrasini, Sicily. Neurology 1994; 44:61-4.

72. Louis ED, Ottman R. How familial is familial tremor? The genetic epidemiology of essential tremor. Neurology 1996; 46:1200-5.

73. Busenbark KL, Nash J, Hubble JP, Koller WC. Is essential tremor benign? Neurology 1991; 41:1982-4.

74. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986; 36:1001-4.

75. Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a Finnish population. Acta Neurol Scand 1982; 66:58-67.

76. Critchley M. Observations on essential tremor. Brain 1949; 72:113-39.

77. Critchley E. Clinical manifestation of essential tremor. J Neurol, Neurosurg and Psychiatry 1972; 35:365-72.

78. Rajput AH, Jamieson H, Hirsh S, Qurraishi A. Relative efficacy of alcohol and propranolol in action tremor. Can J Neurol Sci 1975; 2:31-35.

79. Koller WC, Biary N. Effect of alcohol on tremors: Comparison with propranolol. Neurology 1984; 34:221-2.

80. O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. Br Med J 1981; 282:178.

81. Miller L, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 1990; 83:525-32.

82. Bollini P, Pampallona S, Orz MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 1994; 24:307-16.

83. Sethi KD, Patel B, Meador KJ. Metoclopramide-induced parkinsonism. South Med J 1989; 82:1581-2.

84. Miller L, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149:2486-92.

85. Bateman DN, Darling WM, Boys R, Rawlins MD. Extrapyramidal reactions to metoclopramide and prochlorperazine. Q J Med 1989; 71:307-11.

86. Masmoudi K, Gras-Champel V, Douadi Y, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39:9-12.

87. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38:391-4.

88. Godfrain T, Towea G, Vannuettet JM. Cinnarizine: A selective calcium entry blocker. Drugs Today 1982; 18:27-42.

89. Melamed UD, Achiron A, Shapira A, Davidoviz. Persistent and progressive Parkinsonism after discontinuation of chronic neuroleptic therapy: An additional tardive syndrome? Neuropharmacol 1991; 14:273-8.

90. Silver H, geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on Parkinsonism and tardive dyskinesia type involuntary movements: A double blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiat 1995; 56:167-70.

91. Sandyk R, Pardeshi R. Pyridoxine improves drug-induced Parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci 1990; 52:225-32.